Results 251 to 260 of about 3,573,509 (380)
The effects of the protease inhibitor, aprotinin, on the course of shock induced by endotoxin in cats [PDF]
B. Hughes, J. R. Parratt
openalex +1 more source
Platelet quality deteriorates during storage due to protein and platelet adhesion to current bag materials. Here, polymer coatings are identified that reduce adhesion and translated them to mini‐storage bags. Platelet quality are not impacted, despite significantly reducing adhesion.
Nicolas Pereyra+7 more
wiley +1 more source
Fetal-Specific Forms of α1-Protease Inhibitors in Mouse Plasma [PDF]
Salim Nathoo, Thomas H. Finlay
openalex +1 more source
Extracellular vesicles (EVs) are pivotal mediators of intercellular communication and disease, yet the fundamental mechanisms controlling their biogenesis and cargo selection remain unclear. This limitation hinders their diagnostic utility and therapeutic development.
Luís Carvalho Ferraz+2 more
wiley +1 more source
Investigation of the activity of 4-aminoquinolines as cysteine protease inhibitors with application in the treatment of Chagas disease. [PDF]
Sheu-Idrees R+10 more
europepmc +1 more source
Additive protection of aprotinin, protease inhibitor to cold cardioplegia from ischemic myocardium.
Makoto Sunamori+5 more
openalex +2 more sources
Immunosuppressive Cytokine‐Tethered Hydrogel for Treating Rheumatoid Arthritis
An injectable hydrogel is developed by chemically tethering IL‐4, an immunosuppressive cytokine, to a hyaluronic acid‐based backbone. The hydrogel reduces joint friction and exerts immunomodulatory effects. In a rheumatoid arthritis (RA) mouse model, it reduced inflammation, preserved cartilage, and promoted anti‐inflammatory immune responses.
Woojin Back+3 more
wiley +1 more source
Effects of Trichinella spiralis and its serine protease inhibitors on intestinal mucosal barrier function. [PDF]
Wang R+8 more
europepmc +1 more source
Protease inhibitors as therapeutic agents
Proteases are involved in a high number of diseases, and thus, are relevant targets. For that reason our main goal was the discovery of protease inhibitors as therapeutic agents. We focused our study in four proteases: dipeptidyl peptidase IV (diabetes mellitus type 2), prolyl oligopeptidase (cognitive disorders) and cathepsins L and B (cancer).For the
openaire +2 more sources